金斯瑞生物科技(01548.HK)年度收益升18.4%至2.73億美元 研發開支大幅增加
格隆匯3月28日丨金斯瑞生物科技(01548.HK)公佈,截至2019年12月31日止年度,集團實現總收益2.73億美元,同比增長18.4%,四大分部即生命科學服務及產品、生物製劑開發服務、工業合成生物產品及細胞療法分別實現收益1.70億美元、2250萬美元、2310萬美元及5740萬美元,分佔總收益約62.3%、8.2%、8.5%及21.0%;毛利1.80億美元,同比增長13.8%。
公告稱,收益增加主要是由於經來自主要戰略客户的生命科學服務及產品以及新的具有競爭力的服務及產品持續穩定增長;傳奇與楊森就JNJ-4528開展的合作產生的合約收益增加;及工業合成生物產品的客户及其購買量的增加。毛利增加主要是由於收益增加,但略微被我們的生物製劑開發較高的籌備費用及GMP設施開支(主要原因是產品及銷售團隊升級)所抵銷。
於報告期內,集團大量投資研發及人才儲備。兩者均是業務長期可持續增長的主要推動因素。截至2019年12月31日止年度,集團的研發開支約為1.86億美元,較截至2018年12月31日止年度錄得的約7410萬美元增加151.0%,其中與細胞療法分部有關的研發開支於截至2019年12月31日止年度約為1.57億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.